These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 15476492)

  • 21. Minimizing tacrolimus decreases the risk of new-onset diabetes mellitus after liver transplantation.
    Song JL; Gao W; Zhong Y; Yan LN; Yang JY; Wen TF; Li B; Wang WT; Wu H; Xu MQ; Chen ZY; Wei YG; Jiang L; Yang J
    World J Gastroenterol; 2016 Feb; 22(6):2133-41. PubMed ID: 26877618
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Posttransplant diabetes mellitus in kidney allograft recipients: incidence, risk factors, and management.
    First MR; Gerber DA; Hariharan S; Kaufman DB; Shapiro R
    Transplantation; 2002 Feb; 73(3):379-86. PubMed ID: 11884934
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Statin therapy associated with a reduced risk of chronic renal failure after cardiac transplantation.
    Lubitz SA; Pinney S; Wisnivesky JP; Gass A; Baran DA
    J Heart Lung Transplant; 2007 Mar; 26(3):264-72. PubMed ID: 17346629
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors associated with proteinuria in renal transplant recipients treated with sirolimus.
    Liew A; Chiang GS; Vathsala A
    Transpl Int; 2009 Mar; 22(3):313-22. PubMed ID: 19054382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of insulin resistance indices in predicting new-onset diabetes after kidney transplantation.
    Nagaraja P; Ravindran V; Morris-Stiff G; Baboolal K
    Transpl Int; 2013 Mar; 26(3):273-80. PubMed ID: 23230898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence and risk factors of pre-diabetes after renal transplantation: a single-centre cohort study in 200 consecutive patients.
    Tillmann FP; Quack I; Schenk A; Grabensee B; Rump LC; Hetzel GR
    Nephrol Dial Transplant; 2012 Aug; 27(8):3330-7. PubMed ID: 22492827
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs.
    Araki M; Flechner SM; Ismail HR; Flechner LM; Zhou L; Derweesh IH; Goldfarb D; Modlin C; Novick AC; Faiman C
    Transplantation; 2006 Feb; 81(3):335-41. PubMed ID: 16477217
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term follow-up after conversion from tacrolimus to cyclosporin in renal transplant patients with new-onset diabetes mellitus after transplantation.
    Batista F; Auyanet I; Torregrosa JV; Oppenheimer F
    Transplant Proc; 2012 Nov; 44(9):2582-4. PubMed ID: 23146461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years.
    Cosio FG; Pesavento TE; Osei K; Henry ML; Ferguson RM
    Kidney Int; 2001 Feb; 59(2):732-7. PubMed ID: 11168956
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Statins and risk of treated incident diabetes in a primary care population.
    Zaharan NL; Williams D; Bennett K
    Br J Clin Pharmacol; 2013 Apr; 75(4):1118-24. PubMed ID: 22845189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of new-onset diabetes mellitus during treatment with low-dose statins in Japan: A retrospective cohort study.
    Kato S; Miura M
    J Clin Pharm Ther; 2018 Aug; 43(4):536-542. PubMed ID: 29484697
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Posttransplant diabetes mellitus in renal allograft recipients: A prospective multicenter study at 2 years.
    Marcén R; Morales JM; del Castillo D; Campistol JM; Serón D; Valdés F; Anaya F; Andrés A; Arias M; Bustamante J; Capdevila L; Escuin F; Gil-Vernet S; Gonzalez-Molina M; Lampreave I; Oppenheimer F; Pallardó L;
    Transplant Proc; 2006 Dec; 38(10):3530-2. PubMed ID: 17175323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of pretransplant hepatitis C virus on the development of new-onset diabetes mellitus after transplant in Egyptian living-donor renal allotransplant recipients at Mansoura Urology and Nephrology Center.
    Abbas MH; Ismail MI; El Deeb SA; Nagib AM; Hassan NM; Refaie AF; El Maghrabi HM; Denewar AA; Bakr MA
    Exp Clin Transplant; 2015 Feb; 13(1):26-34. PubMed ID: 25654411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Statin Use and the Risk for Incident Diabetes Mellitus in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: A Population-Based Retrospective Cohort Study in Taiwan.
    Lin ZF; Wang CY; Shen LJ; Hsiao FY; Lin Wu FL
    Can J Diabetes; 2016 Jun; 40(3):264-9. PubMed ID: 26992286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and tolerability of high-intensity statin therapy in heart transplant patients receiving immunosuppression with tacrolimus.
    Heeney SA; Tjugum SL; Corkish ME; Hollis IB
    Clin Transplant; 2019 Jan; 33(1):e13454. PubMed ID: 30485535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Chhabra D; Skaro AI; Leventhal JR; Dalal P; Shah G; Wang E; Gallon L
    Clin J Am Soc Nephrol; 2012 Mar; 7(3):504-12. PubMed ID: 22282478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins.
    Chae YK; Valsecchi ME; Kim J; Bianchi AL; Khemasuwan D; Desai A; Tester W
    Cancer Invest; 2011 Nov; 29(9):585-93. PubMed ID: 21936625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sitagliptin might be a favorable antiobesity drug for new onset diabetes after a renal transplant.
    Soliman AR; Fathy A; Khashab S; Shaheen N; Soliman MA
    Exp Clin Transplant; 2013 Dec; 11(6):494-8. PubMed ID: 24344941
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipid-lowering drugs and risk of new-onset diabetes: a cohort study using Japanese healthcare data linked to clinical data for health screening.
    Ooba N; Setoguchi S; Sato T; Kubota K
    BMJ Open; 2017 Jun; 7(6):e015935. PubMed ID: 28667223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation outcome after ablation of atrial fibrillation.
    Richter B; Derntl M; Marx M; Lercher P; Gössinger HD
    Am Heart J; 2007 Jan; 153(1):113-9. PubMed ID: 17174648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.